AHR and chronic kidney disease: Kynurenic acid, a well-known uremic toxin, was found to be retained in patients with CKD compared with healthy controls by metabolomics studies, and its elevated levels could activate the aryl hydrocarbon receptor pathway to increase tissue factor levels in the vessel wall to enhance thrombosis (Kolachalama et al., 2018; Roshanravan et al., 2018).